DFS vs OS Primary Endpoints in KEYNOTE 564
Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.
Adjuvant Therapy Treatment Approaches for Patients with Advanced Clear Cell RCC
Moshe Ornstein, MD, MA, discusses his approach to adjuvant therapy while treating patients with advanced clear cell RCC.
Design, Criteria, and Endpoints of KEYNOTE 564
Nizar Tannir, MD, describes the data, criteria, and end points of the KEYNOTE-564 trial.
Clear Cell RCC and the KEYNOTE 564 Trial
Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.
Adjuvant Therapy in Clear Cell RCC
Experts discuss the use of pembrolizumab as an adjuvant therapy in advanced clear cell RCC.
Switching Therapies in Advanced Clear Cell RCC without Dose Reduction
Dr Scott Tykodi explains the scenarios in which he would switch a patient to another regimen without dose reduction first.
Selecting an Appropriate Combination Therapy for Patients with Advanced Clear Cell RCC
The panel discusses which of the four approved combination regimens in advanced clear cell RCC they would choose for higher-risk patients, and the factors that play into the decision.
Tolerability of IO/TKI versus IO/IO Combination Treatments in Advanced Clear Cell RCC
Dr Scott Tykodi shares his take on discontinuation of IO-TKI combination regimens because of toxicities.
Tolerability of IO/TKI Combination Therapy for Advanced Clear Cell RCC
An expert explains how he assesses a patient’s tolerability of the IO-TKI combination regimens and at what point he discontinues treatment.
Advanced Clear Cell RCC and the CHECKMATE 9ER Trial
Moshe Ornstein, MD, MA, continues his discussion of I/O-TKI combination regimens by presenting data from the CheckMate 9ER trial.
Advanced Clear Cell RCC and the KEYNOTE 426 Trial
Moshe Ornstein, MD, MA, shares data from the KEYNOTE-426 clinical trial that set a new standard of care for treatment-naïve metastatic clear cell RCC.
Advanced Clear Cell RCC with Intermediate-Risk and the CHECKMATE-214 Trial
Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial.
Treatment Regimens for Patients with Advanced Clear Cell RCC and Bone or Liver Metastasis
Key opinion leaders discuss the options for patients with advanced clear cell RCC who have higher-risk metastatic disease.
Managing Adverse Effects During a Lenvatinib plus Pembrolizumab Combination Therapy Regimen
Dr Scott Tykodi muses on how he would alter treatment for a patient with advanced clear cell RCC after side effects develop.
IO-TKI Combination Therapies: Are They Synergistic or Additive?
Drs Tannir and Tykodi share their differing views on the effect an IO and a TKI agent have when combined for advanced clear cell RCC treatment.
Dosing Strategies for Lenvatinib in Advanced Clear Cell RCC
An oncologist explains his dosing strategies for lenvatinib in advanced clear cell RCC, with reference to the design of the KEYNOTE-426 trial.
Rationale for Lenvatinib plus Pembrolizumab Therapy in Frontline Setting in Advanced Clear Cell RCC
Dr Moshe Ornstein shares his take on the survival, efficacy, and toxicity data of the CLEAR trial in advanced clear cell RCC.
Frontline Therapy in Advanced Clear Cell RCC: The CLEAR Trial
Scott Tykodi, MD, PhD, reviews data from the CLEAR trial investigating 2 IO combination therapies for advanced renal cell carcinoma treatment.
Single-Agent TKI Therapy in Favorable Risk Advanced Clear Cell RCC
Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.
Selecting a Treatment Regimen for Favorable Risk Advanced Clear Cell RCC
Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.
Case Presentation: A Patient with Favorable Risk Advanced Clear Cell RCC
An expert presents the case of a 68-year-old woman with favorable-risk advanced clear cell RCC for discussion.
Comparing Approved First-Line IO-TKI and IO-IO Combination Treatment Regimens in Advanced Clear Cell RCC
Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.
Risk Stratification of Patients with Advanced Renal Cell Carcinoma
Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.
2 Clarke Drive Cranbury, NJ 08512